What does CUSIP 47103J105 represent in this 13F holders report?

CUSIP 47103J105 is the security identifier for JANX - Janux Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held JANX - Janux Therapeutics, Inc. - Common Stock in Q4 2023?

64 institutional investors reported JANX - Janux Therapeutics, Inc. - Common Stock for Q4 2023. Use the holders table for investor-level position and value details.

Janux Therapeutics, Inc. - Common Stock (JANX)

CUSIP: 47103J105

Q4 2023 13F Holders as of 31 Dec 2023

Security type / class: Equity / Common Stock
Total 13F shares: 33,501,695
Total 13F value: $359,539,970
Share change: -1,610,666
Put/Call ratio: 12%
SEC-reported price per share: $10.73
Number of holders: 64
Value change: -$17,204,195
Number of buys: 40
Number of sells: 18
Shares outstanding: 61,171,000

Security key

47103J105

Report period

Q4 2023

Institutions

Top holders

JANX full security history Ownership snapshot Full 13F holder table Janux Therapeutics, Inc. SEC filings Janux Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of JANX - Janux Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

RA CAPITAL MANAGEMENT, L.P.

Disclosed value leader

RA CAPITAL MANAGEMENT, L.P.

Comparable rows

15/15

Latest evidence

30 Sep 2023

13F 3/4/5 Lead comparable stake: 15% Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 15%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.

Comparable ownership Top 5

RA CAPITAL MANAGEMENT, L.P. 15%

FMR LLC 10%

BVF INC/IL 7.5%

CITADEL ADVISORS LLC 5.6%

ORBIMED ADVISORS LLC 5.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
RA CAPITAL MANAGEMENT, L.P.	13F Company 13F	15%	$92,389,772 9,165,652 shares	—	30 Sep 2023
FMR LLC	13F Company 13F	10%	$64,021,326 6,351,322 shares	—	30 Sep 2023
BVF INC/IL	13F Company 13F	7.5%	$46,164,565 4,579,818 shares	—	30 Sep 2023
CITADEL ADVISORS LLC	13F Company 13F	5.6%	$34,586,587 3,431,209 shares	—	30 Sep 2023
ORBIMED ADVISORS LLC	13F 3/4/5 Company · Director 13F 3/4/5	5.4%	$33,444,704 3,317,927 shares	—	30 Sep 2023
Janus Henderson Group Ltd.	13F Company 13F	3.4%	$20,823,593 2,067,468 shares	—	30 Sep 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

33,501,695

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 value	Q4 2023 value	Value change	Value Chg %